Analysts Impressed By Amryt As EB Drug Action Date Approaches
Irish Group Raises Revenue Guidance For 2021
Executive Summary
Amryt has set out its future plans to the investment community with much depending on the successful relaunch of its just-acquired acromegaly drug Mycapssa and a potential FDA approval for its epidermolysis bullosa gel Filsuvez.
You may also be interested in...
Amryt Optimistic For Year Ahead Despite Filsuvez CRL Setback
The rare disease firm hopes continued growth of key products Myalept and Mycapssa will bolster 2022 revenues as it contends with a US regulatory delay for Filsuvez.
Ambitious Amryt To File Butterfly Skin Drug Imminently
The Dublin-based drugmaker, powered by climbing revenues of Lojuxta and Myalept, is preparing its launch teams for Filsuvez, which has the potential to become the first treatment approved for epidermolysis bullosa and the company is banking on speedy regulatory reviews.
Leqvio Launch Will Be Fundamental To Success Of New Novartis
Discussion of the launch trajectory for the twice-yearly cholesterol therapy dominated the marketing portion of Novartis’s investor event and the firm is confident the foundations have been laid to push strong sales growth by the second half of next year.